Article

Biomarkers for osteoarthritis: Current position and steps towards further validation.

Best practice & research. Clinical rheumatology (Impact Factor: 3.06). 02/2014; 28(1):61-71. DOI: 10.1016/j.berh.2014.01.007
Source: PubMed

ABSTRACT Historically disease knowledge development and treatment innovation in osteoarthritis (OA) has been considered to be slow. One of the many reasons purported as responsible for this slow pace has been the alleged lack of valid and responsive biomarkers to ascertain efficacy, which itself has been dependent upon the slow evolution of the understanding of the complex nature of joint tissue biology. This narrative review outlines the rationale for why we need OA biomarkers with regard to biomarker validation and qualification. The main biomarkers in current development for OA are biochemical and imaging markers. We describe an approach to biomarker validation and qualification for OA clinical trials that has recently commenced with the Foundation of NIH OA Biomarkers Consortium study cosponsored by the Osteoarthritis Research Society International (OARSI). With this approach we endeavor to identify, develop, and qualify biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics for osteoarthritis.

1 Follower
 · 
64 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The 7(th) OARSI International Workshop on Osteoarthritis Imaging was held in Reykjavik, Iceland, from July 9-12, 2014; attracting attendees from academia, pharmaceutical and MRI industries, as well as a large number of young investigators. The Workshop program consisted of six modules, including imaging in OA, imaging and pain in OA, new techniques in imaging, risk factors and structural outcomes, anti-nerve growth factor (a-NGF) therapy, and joint replacement. A wealth of data was presented from OA researchers from all over the world and participants gained insightful knowledge on up-to-date research work focusing on imaging of OA. This paper presents a summary of the salient points from the workshop. Identifying the appropriate imaging modality and parameters will be critical for ensuring responsive, reproducible and reliable outcomes for clinical trials. Continued efforts from the OA research community are needed to establish the most effective use of imaging in OA clinical trials, including anti-NGF therapy and joint replacement trials, and to validate newer imaging techniques such as compositional MRI for use in the future clinical trials. Copyright © 2015. Published by Elsevier Ltd.
    Osteoarthritis and Cartilage 02/2015; DOI:10.1016/j.joca.2015.02.004 · 4.66 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Our previous work has revealed that expression of follistatin-like protein 1 (FSTL1) is elevated in the synovial tissues from osteoarthritis (OA) patients. The aim of this study was to elucidate the underlying molecular mechanisms by which FSTL1 plays a role in the pathogenesis of OA. Cultured fibroblast-like synoviocytes (FLSs) from synovial tissues of OA patients were stimulated with human recombinant FSTL1, and then the expression of inflammatory cytokines in FLS and their concentrations in the cell supernatants were measured by real-time polymerase chain reaction (PCR) and enzyme-linked immuno sorbent assay (ELISA), respectively. Nuclear factor kappa B (NF-κB) activation was examined by western blot and chromatin immunoprecipitation (ChIP) assay at p65 binding site. Finally, the proliferation of FLSs and the expression level of the proliferation-related tumor suppressors (p53 and p21) were determined by MTS assay kit and western blot in the presence or absence of FSTL1, respectively. FSTL1 remarkably promoted expression levels of several inflammatory cytokines (tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6)) in vitro. Western blot analysis showed that FSTL1 activated the inflammatory-related NF-κB signaling pathway, as validated by ChIP assay detecting p65-binding level on cytokine promoter region. Moreover, FSTL1 promoted the proliferation of OA FLS by down-regulating the expression of p53 and p21. Interestingly, the concentration of synovial fluid IL-6 was remarkably elevated in OA patients, and was correlated with synovial fluid and serum FSTL1 levels. These findings show that FSTL1 functions as an important proinflammatory factor in the pathogenesis of OA by activating the canonical NF-κB pathway and enhancing synoviocytes proliferation, suggesting that FSTL1 may be a promising target for the treatment of OA.
    Arthritis research & therapy 04/2015; 17(1):91. DOI:10.1186/s13075-015-0605-6 · 4.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Biochemical and pain biomarkers can be applied to patients with painful osteoarthritis profiles and may provide more details compared with conventional clinical tools. The aim of this study was to identify an optimal combination of biochemical and pain biomarkers for classification of patients with different degrees of knee pain and joint damage. Such profiling may provide new diagnostic and therapeutic options. A total of 216 patients with different degrees of knee pain (maximal pain during the last 24 hours rated on a visual analog scale [VAS]) (VAS 0-100) and 64 controls (VAS 0-9) were recruited. Patients were separated into 3 groups: VAS 10 to 39 (N = 81), VAS 40 to 69 (N = 70), and VAS 70 to 100 (N = 65). Pressure pain thresholds, temporal summation to pressure stimuli, and conditioning pain modulation were measured from the peripatellar and extrasegmental sites. Biochemical markers indicative for autoinflammation and immunity (VICM, CRP, and CRPM), synovial inflammation (CIIIM), cartilage loss (CIIM), and bone degradation (CIM) were analyzed. WOMAC, Lequesne, and pain catastrophizing scores were collected. Principal component analysis was applied to select the optimal variable subset, and cluster analysis was applied to this subset to create distinctly different knee pain profiles. Four distinct knee pain profiles were identified: profile A (N = 27), profile B (N = 59), profile C (N = 85), and profile D (N = 41). Each knee pain profile had a unique combination of biochemical markers, pain biomarkers, physical impairments, and psychological factors that may provide the basis for mechanism-based diagnosis, individualized treatment, and selection of patients for clinical trials evaluating analgesic compounds. These results introduce a new profiling for knee OA and should be regarded as preliminary.
    Pain 01/2015; 156(1):96-107. DOI:10.1016/j.pain.0000000000000011 · 5.84 Impact Factor